Send to:

Choose Destination
See comment in PubMed Commons below
Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26.

IMWG consensus on risk stratification in multiple myeloma.

Collaborators (162)

Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Bergsagel PL, Bird J, Bladé J, Boccadoro M, Caers J, Cavo M, Chanan-Khan A, Chen WM, Chesi M, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de la Rubia J, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Oschin CS, Einsele H, Facon T, Fantl D, Hematolgia SA, Fermand JP, de Larrea CF, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Ghobrial I, Gibson J, Gimsing P, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Hata H, Hattori Y, Heffner T, Ho J, Hoering A, Hou J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Joshua D, Jurczyszyn A, Kaufman J, Kawano M, Kovacs E, Krishnan A, Kristinsson S, Kröger N, Kumar S, Kyle RA, Kyriacou C, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Laurent G, Costa FL, Lee JH, Leiba M, LeLeu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Mahindra A, Maiolino A, Mateos M, Mazumder A, McCarthy P, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Moreau P, Morgan G, Munshi N, Nahi H, Niesvizky R, Nouel A, Novis Y, Ocio E, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Rajkumar S, Reece D, Reiman T, Richardson PG, Morales AR, Romeril KR, Roodman D, Rosinol L, Russell S, Miguel JS, Schots R, Sevcikova S, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Usmani S, Van Camp B, Van Ness B, Van Riet I, Vande Broek I, Vanderkerken K, Vescio R, Vesole D, Voorhees P, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zamagni E, Zonder J, Zweegman S.


Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk